Skip to main content
Clinical Trials/NCT05757947
NCT05757947
Recruiting
Not Applicable

Multicenter Clinical Trial of Myocardial Revascularization Using I-conduit and No-touch Saphenous Vein Graft

Meshalkin Research Institute of Pathology of Circulation1 site in 1 country106 target enrollmentDecember 22, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Meshalkin Research Institute of Pathology of Circulation
Enrollment
106
Locations
1
Primary Endpoint
Patency of "no-touch" saphenous vein graft
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Authors hypothesize that "no-touch" saphenous vein as I graft is superior over conventional "no-touch" saphenous vein as free graft in the incidence of graft patency.

Detailed Description

A multicenter single blind prospective randomized superiority study is conducted. Our hypothesis is that there is difference in the incidence of "no-touch" saphenous vein graft patency using it as the conventional free graft (group C) and I graft (group I) for myocardial revascularization more than 28%. If there is truly difference between groups, then total 106 patients for both groups are required to be 90% sure that the upper limit of a one-sided 95% confidence interval would reveal a difference in favour of the "no-touch" saphenous vein I graft of 28%. The blinding process is applied to a patient, who is informed about received harvesting method of saphenous vein, but don't know the type of the graft cofiguration. The study was approved by Institutional Review Board. Depending on a type of the procedure, the patients are divided into two groups: conventional free graft (group C) 53 patients and I graft (group I) 53 patients. Randomization is conducted befor operation by using accidental sampling.

Registry
clinicaltrials.gov
Start Date
December 22, 2022
End Date
December 22, 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Meshalkin Research Institute of Pathology of Circulation
Responsible Party
Principal Investigator
Principal Investigator

Dmitry Khvan

candidate of medical sciences, senior researcher, сardiovascular surgeon of the NMRC named after academician E.N. Meshalkin of the Ministry of Health of Russian Federation

Meshalkin Research Institute of Pathology of Circulation

Eligibility Criteria

Inclusion Criteria

  • Patients with coronary artery disease requiring three-vessel myocardial revascularization
  • Patient consent to the study

Exclusion Criteria

  • The diameter of the target arteries for conduits of the internal mammary arteries is less than 1 mm
  • Hemodynamically significant atherosclerosis of the subclavian arteries in the first segment
  • Stenosis of the right coronary artery less than 90%
  • Concomitant pathology requiring additional simultaneous surgical correction
  • Lack of IMA
  • COPD with FEV1 \<60%
  • Prior heart surgery
  • Oncological diseases with a life expectancy of less than 5 years
  • CKD stage 4 and higher
  • The diameter of the SVG is less than 2 mm or its varicose expansion is more than 6 mm

Outcomes

Primary Outcomes

Patency of "no-touch" saphenous vein graft

Time Frame: 12 months after surgery

Assessment of the patency of coronary shunts

Secondary Outcomes

  • MACE(6 and 12 months after after surgery)
  • Complications of the conduit fence site(6 and 12 months after after surgery)
  • Recurrence of angina pectoris(6 and 12 months after after surgery)
  • Survival rate(6 and 12 months after after surgery)

Study Sites (1)

Loading locations...

Similar Trials